Biotechnology NK
(NASDAQ)
19.76
+0.62   (+3.24%)
Pre-market: 20.00 +0.24 (+1.21%)
Volume (24h) Market Cap. Day Range 52w Range
1.46M 2.15B 18.14 - 20.78 2.52 - 20.78
Jan-25-21 03:37AM SHAREHOLDER ALERT: WeissLaw LLP Reminds PROS, IPHI, NK and XLNX Shareholders About Its Ongoing InvestigationsPR Newswire
Jan-21-21 05:09AM MERGER INVESTIGATION: Halper Sadeh LLP Investigates RP, BPFH, ALSK, NK, ANH; Shareholders Are Encouraged to Contact the FirmPR Newswire
02:17AM RM LAW Announces Investigation of NantKwest, Inc.PR Newswire
Jan-21-21 12:56PM INVESTIGATION ALERT: Nationally Ranked Shareholder Rights Law Firm Labaton Sucharow is Investigating NantKwest, Inc. (NASDAQ: NK) for Potential Securities Violations and Breach of Fiduciary DutyBusiness Wire
Jan-20-21 05:25AM SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following MergerACCESSWIRE
10:00AM INVESTIGATION ALERT: Halper Sadeh LLP Investigates CHNG, RP, MDCA, NK; Shareholders Are Encouraged to Contact the FirmACCESSWIRE
Jan-19-21 08:01AM NK INVESTOR ALERT: Kaskela Law LLC Announces Stockholder Investigation of NantKwest, Inc.GlobeNewswire
Jan-18-21 12:00PM ALERT: Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm – RP, BPFH, NK, SPWHGlobeNewswire
Jan-15-21 09:00AM SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following MergerPR Newswire
Jan-14-21 04:43AM INVESTIGATION ALERT: Halper Sadeh LLP Investigates ALXN, CHNG, RP, RNET, MDCA, NK; Shareholders Are Encouraged to Contact the FirmPR Newswire
07:56AM The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial UpdatesBenzinga
Jan-14-21 06:44AM NantKwest Reports Positive Interim Data In Pancreatic Cancer Trials, Stock SoarsBenzinga
Jan-13-21 09:00AM SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of NK, RNET, HMSY, and QEP MergersGlobeNewswire
06:01AM NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer TrialsBusiness Wire
Jan-13-21 02:20AM SHAREHOLDER ALERT: Halper Sadeh LLP Investigates RNET, HMSY, NK, PRGX; Shareholders Are Encouraged to Contact the FirmGlobeNewswire
Jan-12-21 07:11AM SHAREHOLDER ALERT: WeissLaw LLP Reminds WTRE, TNAV, RNET and NK Shareholders About Its Ongoing InvestigationsPR Newswire
Jan-07-21 04:18AM SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CHNG, BPFH, RP, MDCA, NK; Shareholders Are Encouraged to Contact the FirmPR Newswire
Jan-06-21 09:00AM NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021Business Wire
Jan-05-21 11:18AM WeissLaw LLP Reminds RNET, NK, HMSY, and QEP Shareholders About Its Ongoing InvestigationsPR Newswire
05:36AM NANTKWEST ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of NK and Encourages Investors to Contact the FirmGlobeNewswire
Jan-02-21 07:30AM MERGER INVESTIGATION ALERT: Halper Sadeh LLP Encourages NK, PRGX, CBLI, and IPHI Shareholders to Contact the FirmACCESSWIRE
Dec-30-20 09:00AM STOCKHOLDER ALERT: Monteverde & Associates Launches Legal Investigation for the Following TransactionACCESSWIRE
10:10AM SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers – WTRE, ARA, RESI, NKGlobeNewswire
Dec-30-20 08:49AM New Strong Sell Stocks for December 30thZacks
07:18AM Here's a Cancer-Killing Stock to Buy for 2021Motley Fool
Dec-29-20 08:58AM WeissLaw LLP Reminds RNET, NK, HMSY, and QEP Shareholders About Its Ongoing InvestigationsPR Newswire
06:40AM NANTKWEST INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of NantKwest, Inc. - NKBusiness Wire
Dec-28-20 08:20AM SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - PRGX, STND, NK, EIDX, ARAPR Newswire
11:22AM SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of NantKwest, Inc. (NK) and Encourages Shareholders to Contact the FirmGlobeNewswire
Dec-28-20 08:07AM NANTKWEST (NK) SHAREHOLDER ALERT - Andrews & Springer LLC Is Seeking More Cash for Shareholders of NantKwest, Inc.GlobeNewswire
Dec-24-20 10:08AM NantKwest Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of NantKwest, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NKBusiness Wire
Dec-23-20 09:00AM SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of NantKwest, Inc. - NKPR Newswire
05:58AM SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of NantKwest, Inc. MergerGlobeNewswire
Dec-22-20 10:02AM SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of NantKwest, Inc. – NKGlobeNewswire
09:48AM 5 Medical Outperformers That Might Lose Steam in 2021Zacks
Dec-21-20 07:56AM SHAREHOLDER ALERT: WeissLaw LLP Investigates NantKwest, Inc.PR Newswire
06:47AM SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of NantKwest, Inc. (Nasdaq - NK)ACCESSWIRE
Dec-21-20 12:49PM Why NantKwest Is Jumping TodayMotley Fool
10:10AM Biopharma M&A Continues: Agios Sells Oncology Portfolio, NantKwest's Reverse Merger With ImmunityBio, Eyegate Picks Up PanoptesBenzinga
Dec-21-20 06:05AM ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy CompanyBusiness Wire
Dec-10-20 11:18AM Is NK A Good Stock To Buy Now?Insider Monkey
09:48AM ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human PrimatesBusiness Wire
Dec-09-20 05:13AM How Much Are NantKwest, Inc. (NASDAQ:NK) Insiders Spending On Buying Shares?Simply Wall St.
Dec-07-20 12:00PM Good vaccine news and a flurry of stock sales by executives. There's a pattern, study findsLA Times
Nov-23-20 09:00AM ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell KillingBusiness Wire
Nov-18-20 09:15AM NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare ConferenceBusiness Wire
Nov-10-20 07:00AM ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose StudyBusiness Wire
Nov-09-20 03:07AM Covid-Tied Biotechs Unwind Gains After Pfizer Vaccine DataBloomberg
10:02AM Covid-Tied Biotechs Unwind Gains After Pfizer Vaccine DataBloomberg
Nov-09-20 09:00AM ImmunityBio’s hAd5 COVID-19 Vaccine Candidate Stimulates Memory T-Cell Recall in Patients Infected with SARS-CoV-2Business Wire
NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Cap:    |  Volume (24h):